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Background: Chagas disease is most often transmitted to humans by Trypanosoma cruzi infected triatomine bugs,
and remains a significant cause of morbidity and mortality in Central and South America. Control of Chagas disease
has relied mainly on vector eradication. However, development of insect resistance has prompted us to develop a
paratransgenic strategy to control vectorial transmission of T. cruzi. Here, the potential role of recombinant
endoglucanases as anti-trypanosomal agents for paratransgenic application is examined. The surface of T. cruzi is
covered by a thick coat of mucin-like glycoproteins that have been proposed to play a role in the binding of T.
cruzi to the membrane surface of the vector gut. We hypothesize that disruption of these glycoconjugates could
arrest parasite development in the vector and abort the transmission cycle. In this work, we examine the effects of
recombinant Arthrobacter luteus β-1, 3-glucanase expressed via Rhodococcus rhodnii on T. cruzi Sylvio II strain.
Methods and results: The coding sequence for β-1, 3-glucanase was cloned in-frame to a heterologous promoter/
signal sequence from the Mycobacterium kansasii alpha antigen gene resident in an E. coli/R. rhodnii shuttle vector.
The resulting construct was confirmed by sequencing, and electroporated into R. rhodnii. Expression products from
positive clones were purified from log phase cultures followed by dialysis into physiological buffers. Lysates and
media were quantitated by ELISA against rabbit antibody specific to β-1,3-glucanase. Glucanase-positive samples
were applied to live T. cruzi parasites in culture and viability accessed by spectrophotometric and fluorescent
microscopic measurements. R. rhodnii-expressed β-1,3-glucanase exhibited toxicity against T. cruzi compared to
controls when applied at 5 and 10% of the total culture volume. The decrease in cell viability ranged from a
maximum of 50% for the media treatments to 80% for the filtered lysates.
Conclusions: These results suggest that recombinant β-glucanase could be a powerful addition to the arsenal of
effector molecules for paratransgenic control of Chagas disease. In future studies, the ability of β-glucanase to
function in combination with other effector molecules will be explored. Dual targeting of T. cruzi should not only
slow resistance but also permit synergistic or additive lethal effects on T. cruzi.Background
Chagas disease, a parasitic disease endemic to South and
Central America, is caused by the protozoan Trypanosoma
cruzi and transmitted to humans via the feces of triatomine
bugs. It affects approximately 8–11 million people, results
in 50,000 deaths and accounts for the loss of 500,000
disability-adjusted life-years annually [1]. Cases of Chagas* Correspondence: Ravi.Durvasula@va.gov
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reproduction in any medium, provided the ordisease have expanded globally, and are now reported in
the Americas, Europe, Australia and Asia due to emigra-
tion of infected individuals from endemic parts of the
world [2].
Chagas disease manifests in three distinct phases -
acute, indeterminate and chronic. Infected individuals
present in an initial acute phase that develops into a
chronic phase in 20-40% of the patients. The chronic
phase is characterized by the development of lesions in
the nervous tissue of the heart, intestine and esophagus
that result in progressive organ enlargement with poten-
tially fatal complications. Patients who do not progress. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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minate phase [3]. The two drugs used worldwide in the
treatment of Chagas disease, benznidazole and nifurtimox,
are effective only against the acute stage of the disease [4].
These treatments are marred by their many side effects
including bone marrow toxicity, neural toxicity and se-
vere nausea and vomiting [5]. Moreover, strains of T. cruzi
that are resistant to both drugs have emerged and resist-
ance to one drug is usually coupled with resistance to the
other [6].
Several efforts have been undertaken to control trans-
mission of the disease to human populations from
triatomine vectors. These transmission-prevention pro-
grams include insecticide-based campaigns, housing im-
provements, health education and blood donor screening
programs [7]. Much of the success of transmission-
control stems from the Southern Cone [8], Central
American [9] and Andean Pact Initiatives [10]. These
strategies have had considerable success in interrupting
vectorial transmission and have reduced new cases of the
disease in many countries. However, the wide use of insec-
ticides has created resistant triatomine populations [11].
Furthermore, large-scale vector eradication programs have
suffered due to funding issues in countries such as
Argentina [12]. The reduced effectiveness of insecticide-
based programs in peridomestic habitats has resulted in
incomplete eradication of the vector. Re-emergence of
Chagas disease is an immediate threat. The need for new
methods of disease control are highlighted by the emer-
gence of drug resistant T. cruzi, toxic side-effects of avail-
able drug treatments, the inability to treat chronic disease,
insecticide resistance in target vector populations and in-
effectiveness of the insecticide-based approach in elimin-
ating the disease
Paratransgenesis is an alternative approach under de-
velopment to reduce transmission of vector-borne dis-
eases by eliminating carriage of pathogens by their
arthropod vector hosts [13]. The strategy focuses on un-
derstanding the microbial flora of the insect host at the
developmental locus of the pathogen and genetically
transforming selected bacteria to produce molecules that
disrupt the target pathogen. Thus the bacteria act as a
carrier or delivery agent – a Trojan horse – for the anti-
pathogen molecules [14]. We developed the paratransgenic
strategy to control Chagas disease transmission by
triatomine bugs over 10 years ago [15]. In this strategy, the
relationship between an important vector, Rhodnius
prolixus, and its gut symbiont, Rhodococcus rhodnii, was
exploited to disrupt the transmission of T. cruzi. R. rhodnii
is a nocardiform actinomycete that aids R. prolixus with
vitamin metabolism after its blood meal [16]. These actino-
mycetes, obtained through coprophagy, are essential for
the survival of the triatomine bugs. Aposymbiotic nymphs
of R. prolixus do not reach sexual maturity [17]. Because ofits symbiotic association and proximity to the infective
trypomastigote form of T. cruzi in the insect hindgut, R.
rhodnii serves as an ideal organism for application in
paratransgenesis [18]. We initially demonstrated that gen-
etically engineered R. rhodnii that expressed an anti-
trypanosomal peptide, cecropin A, when introduced into
R. prolixus, resulted in elimination or significant reduction
of T. cruzi in experimentally infected bugs [15]. More re-
cent in vitro studies have shown that several anti-microbial
peptides (AMPs) are even more effective at targeting
T. cruzi when used in combination [19]. This opens up
the possibility of using multiple molecules synergistic-
ally to eliminate vector carriage of the parasite.
In this study, we investigate the potential role of
endoglucanases as anti-trypanosomal agents. The surface
of T. cruzi is covered by a thick coat of mucin-like glyco-
proteins. Many of these glycoproteins are developmen-
tally regulated and have been proposed to play a role in
the binding of the cell body and the flagellum of T. cruzi
to the membrane surface of the vector gut, an integral
step in T. cruzi maturation [20]. We hypothesize that
disruption of the glycoconjugates by endoglucanases
could arrest parasite development in the vector and
abort the transmission cycle. Arthrobacter luteus lyticase
is a complex endoglucanase consisting of β-1,3-
glucanase and alkaline protease that degrades β-1,3 and
1–6 glycosidic linkages [21]. We previously demon-
strated that purified lyticase from Arthrobacter was
highly effective at lysing T. cruzi in vitro. Here we report
that recombinant Arthrobacter luteus β-1,3-glucanase
expressed via R. rhodnii effectively kills T. cruzi Sylvio II
strain, suggesting that this molecule may be a powerful
addition to the arsenal of effector molecules for
paratransgenic control of Chagas disease.
Methods
Sub-cloning of the β-1,3-glucanase gene into E. coli/R.
rhodnii shuttle vector
The cDNA of β-1,3-glucanase from Oerskovia xanthineolytica
(also known as Arthrobacter luteus strain 73–14) was a gift
from Dr. Steve Slilaty [22]. To facilitate subsequent cloning
steps the 1.7 kb β-1,3-glucanase cDNA was excised from
pOP95-15 by AgeI and SmaI digestion, and subcloned into
the XmaI and EcoRV sites of pBlueScript KS, generating
pBS-glucanase.
The plasmid pRrExpA is an E. coli/R. rhodnii shuttle
vector. Protein expression from this plasmid is under
the control of a heterologous promoter-signal peptide
complex derived from the alpha antigen gene (MKα) of
Mycobacterium kansasii. A modified pBlueSript SK
MCS, lacking the EcoRV through KpnI sites, is located
just downstream of this promoter. The β-1,3-glucanase
cDNA was ligated in frame into the BamHI/SmaI sites
of pRrExpA following excision from pBS-glucanase by
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digestion, to generate pRr-glucanase. Transformants were
selected on Luria-Bertani (LB) plates containing 50 μg/ml
of carbenicillin (CAR). Plasmid DNA isolated by Qiagen
columns from the clones was sequenced to verify
insertion.
Transformation of pRr-glucanase into R. rhodnii
R. rhodnii electro-competent cells were generated by
growing the cells in 500 mls of modified BHI (BHI with
0.1% Tween-80 and 2% glycine) at 30°C until mid-log
phase. Cells were chilled on ice and harvested by centri-
fugation. The pellets were washed three times with a
cold filtered-sterilized solution of 10% glycerol, 0.05%
Tween-80, and resuspended in 1 ml of cold 10% glycerol
after the final wash. These electrocompetent cells were
stored as 100 μl aliquots at −80°C until ready for use.
For electroporation, competent cells were thawed on
ice and mixed with 200 μg of pRr-glucanase DNA. 80 μl
of this mixture were transferred to a chilled electropor-
ation cuvette (Bio-Rad, 0.1 cm gap) and electroporated
twice using a field strength of 18.5 kV/cm with a time
constant of 5 ms on a BioRad Gene Pulser II. Samples
were placed on ice between electrical pulses. Following
electroporation, cells were allowed to recover in 1 ml of
BHI at room temperature for 2 hours. 200 μl aliquots
were spread onto BHI plates containing 25 μg/ml CAR.
Plates were incubated at 28°C, and checked every 2 days
for growth for up to 1 month.
Selection and confirmation of R. rhodnii-glucanase clones
Plasmid specific primers, Mkα5’ (5’ CAG AGC TGA
GCG GGA AGA TTC 3’) and OriR3’ (5’ GCA CGA
CCA CAG CAA TAC 3’), were used for colony PCR
screening of putative R. rhodnii transformants. Cycling
conditions were an initial denaturation step for 3 mins
at 95°C, followed by 30 cycles at 92°C for 30 sec, 54°C
for 30 sec, and 72°C for 1 min, followed by final exten-
sion at 72°C for 3 min. PCR products were analyzed by
electrophoresis on 1% agarose gels.
Rhodococcus specific 16S rDNA sequencing was performed
to confirm the identity of each transformant. Genomic
DNA (gDNA), isolated from each R. rhodnii transformant
(MasterPure Gram Positive DNA isolation kit - Epicentre),
was amplified using 16s-RrF (5’ CTG GGT CTA ATA
CTG GAT ATG 3’) and 16s-RrR (5’ TGC CAT TAC TAG
CGA CTC 3’) primers. Cycling conditions were 3 mins of
denaturation at 95°C, followed by 30 cycles of 95°C for 30
sec, 52°C for 30 sec and 72°C for 1.5 min, followed by a
final extension for 3 mins at 72°C. Amplification was con-
firmed by running a portion of the reaction mixture on a
1% agarose gel. Samples that amplified were subsequently
purified from the reaction using the Qiagen PCR Purifica-
tion kit per manufacturer’s instructions, and sequencedusing the PCR primers described above with the BigDye
Terminator Reaction Cycle Sequencing Kit (Applied
Biosystems). Sequences were then submitted for BLAST
analyses at the GenBank database.
Production of cell extracts and spent media from R.
rhodnii transformants
Cells from 100 ml mid-log cultures of transformed and
untransformed (negative control) R. rhodnii were pelleted
by centrifugation and the spent media frozen at −20°C.
The pelleted cells were suspended in 10 ml of complex
lysis buffer (100 mM Tris, 500 mM NaCl, 0.5 mM EDTA,
0.1% Triton X-100, 0.1% Tween-20, 8% glycerol, 250 mM
urea, 5 mM 2-mercaptoethanol, 100 μg/ml PMSF, 1X
HALT Protease Inhibitor Cocktail, 50 μg/ml lysozyme and
1U benzonase) and lysed by alternating the suspended
cells between cooling on ice and vortexing at ten-minute
intervals. Following complete lysis after 30 mins, cellular
debris was removed by centrifugation at 15,000 rpm
for 30 mins. Half of the lysate was flash-frozen and
stored at −80°C. The remainder was dialyzed for 48
hours at 4°C into 1X TBS (25 mM Tris, 0.5 M NaCl,
pH = 7.2) with Sigma protease inhibitors using a 2,000
MWCO Slide-A-Lyser dialysis cassette (Pierce), with
one change of dialysis buffer at 24 hours. Dialysate was
aliquoted, flash-frozen and stored at −80°C.
Characterization of polyclonal antibody to β-glucanase
A rabbit polyclonal antibody to the CHEPGTQFRGRVDGD
epitope of β-glucanase was produced by GenScript for this
laboratory. The specificity and affinity of this affinity-
purified antibody was determined via ELISA against
Arthrobacter lyticase complex and the synthetic peptide
used to produce the primary antibody. Five-log dilutions of
lyticase (100 U/μl to 0.01 U/μl) or β-glucanase peptide (0.01
nM to 100 nM) were bound overnight at 4°C to 96-well
plates. Wells were washed and blocked with 2.5% BSA
in TBS-T (25 mM Tris, 0.5 M NaCl, pH = 7.2, 0.5%
Tween-20), and the primary antibody was added at a
1:5000 dilution in TBS-T. After a 2 hour incubation at
37°C, the primary antibody was removed, wells washed
as before and a 1:5000 dilution of anti-rabbit IgG HRP
added. Plates were incubated at 37°C in the dark for
one hour before being washed 3 times prior to detection
with single component TMB (BioRad). Plates were then
read at OD450 on a Molecular Devices SpectraMax M2
Fluorescent microplate reader. These experiments were
repeated in triplicate.
Western analysis of cell lysates and spent media
Lysates and spent media from transformed and control
R. rhodnii were separated using SDS-PAGE on 8% Tris-
glycine gels (Invitrogen). Proteins were subsequently
transferred to 0.2 μm pure nitrocellulose membranes.

































Figure 1 Binding affinity of polyclonal anti-glucanase antibody.
The binding affinity of the polyclonal anti-glucanase antibody at a
dilution of 1:5000 was determined against five-log dilutions of
Arthrobacter lyticase. Note that this polyclonal antibody can detect
β-glucanase in as little as 0.05 U/μl of Arthrobacter lyticase. Each
point represents the mean with standard error bars of triplicate
samples. Experiments were performed at least twice.
-glucanase Standard Curve
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Figure 2 ELISA standard curve for β-glucanase. Decreasing
concentrations of synthetic β-glucanase were titrated against 1:5000
dilution of the polyclonal anti-glucanase antibody to generate ELISA
standard curves such as the one shown here. These curves were
used to quantify recombinant β-glucanase expression from each R.
rhodnii clone. All points represent the mean with standard error bars
of triplicate samples. Experiments were performed at least twice.
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TBS-T, a 1:5000 dilution of the anti-glucanase antibody
was added and the membrane incubated overnight at
4°C. Following three washes, a secondary anti-rabbit IgG
coupled to HRP was added to the membrane at a
1:10,000 dilution for 1 hour at room temperature. Blots
were developed by incubation in TMB.
ELISA of cell extracts and spent media
Samples from transformed and control R. rhodnii diluted
in TBS-T were added to triplicate wells on microtiter
plates, and incubated for 2 hours at 37°C. After washing
the wells in TBS-T, 2.5% BSA was added to block for 1
hour at 37°C. The primary antibody (GenScript USA),
diluted to 1:5000 (in TBS-T), was removed after over-
night incubation at 4°C. The secondary antibody used in
these experiments was an anti-rabbit IgG coupled to
HRP. 100 μl of a 1:5000 dilution of this antibody was
added to each well, and allowed to incubate at 37°C for
an hour in the dark. Detection of expressed recombinant
protein was accomplished after 3 final washes by devel-
opment in TMB. Plates were read at 450 nm on the Mo-
lecular Devices SpectraMax M2 Fluorescent Microplate
Reader.
Toxicity of recombinant β glucanase against T. cruzi
The toxicity of recombinant β glucanase produced by
R. rhodnii in cell lysates and spent media against
epimastigote cultures of T. cruzi Silvio II (ATCC #50823)
was determined by a combination of spectrophotometric
turbidity and live/dead fluorescent microscopy assays as
described in Fieck et al. [19]. Briefly, lysates from β
glucanase recombinants were diluted in 1X PBS and
added to triplicate wells of sterile tissue culture certified
96-well plates. 105 parasites were added to each well and
the plates incubated at 28°C for a total of 96 hours. The
optical density of the cultures was measured at 600 nm
every 24 hours. After the incubation period, parasites from
triplicate wells were pooled and stained for 1 hour with
1 μl of 5 mM Calcein-AM (Molecular Probes). After
washing in 1.0 ml 1X PBS, brightfield and green fluor-
escent images were generated on a Nikon Eclipse 80i
microscope. In these experiments, lysates and spent
media from untransformed R. rhodnii were used as
negative controls. No human subjects or animals were
used in this study.
Results
Construction of pRr-glucanase and transformation of R.
rhodnii
Sequence analysis revealed that the β-1,3-glucanase cDNA
was successfully cloned downstream of the MKα promoter-
signal peptide of the pRrExpA shuttle vector. This clone,
pRr-glucanase, was subsequently electroporated intoR. rhodnii. The transformation efficiency of actinomy-
cetes was in the range of one transformant per 108
cells. A total of 40 putative R. rhodnii-glucanase
transformants were selected after 3 days of growth on
BHI plates containing 25 μg/ml CAR. Of these, four
were randomly selected for further characterization.
The remaining cells were propagated in BHI containing
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Figure 3 Expression of β-glucanase from R. rhodnii Clone 1. Dialyzed lysates and spent media from transformed R. rhodnii was examined for
expression of β-glucanase. Expression of β-glucanase was consistently higher in each of the diluted samples, suggesting that there is self-blocking
at high protein expression levels. As expected, the expressed protein is found predominantly in the spent media. Bars represents the mean with
standard error bars of triplicate samples wells.





























































Figure 4 Arthrobacter lyticase inhibited the growth of T. cruzi
Sylvio. T. cruzi Sylvio was cultured in media with indicated
concentrations of Arthrobacter lyticase. Parasite turbidity was
determined following 96-hour incubation and compared to
untreated parasites. Results were averaged from triplicate samples in
two independent experiments, and are presented as the percent
change in turbidity between treated and untreated cultures
following the 96-hour incubation.
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ture use.
Amplification of the 16S rDNA using Rhodococcus
specific primers on isolated genomic DNA confirmed
that the selected transformants were, indeed, R. rhodnii.
A 1.4kb PCR product was obtained from two of the four
selected clones. Sequencing of the PCR product confirmed
that the recombinant organism was R. rhodnii. To confirm
that the two remaining Rhodococcus transformants har-
bored pRr-glucanase, colony PCR was performed using
plasmid specific primers that flank the insert. Only one of
the four transformants yielded a 1.7 kb fragment that is in-
dicative of the insert.
Characterization of anti-β-1,3-endogluconase polyclonal
antibody
After a thorough and unsuccessful search for commer-
cially available antibodies against β-glucanase, a syn-
thetic antibody was specifically raised for the detection
of this recombinant molecule. The affinity of this anti-
body was initially tested by examining its ability to bind
commercially available Arthrobacter lyticase. Figure 1
shows that a 1:5000 dilution of this antibody is capable
of detecting Arthrobacter lyticase at a limit of 0.005
units/μl. The antibody was synthesized against an epi-
tope on the β-glucanase peptide that is part of the
Arthrobacter lyticase complex. Therefore, synthetic
β-glucanase peptide was used to generate a standard
curve that could be used to determine the expres-
sion level of glucanase from transformed R. rhodnii
(Figure 2). The antibody detected β-glucanase at concen-
trations as low as 10nM. Resolution of concentrations
lower than 10nM was impossible from the present ELISA.The OD readings corresponding to these standards curves
were used to calculate the concentration of recombinant
β-glucanase from the R. rhodnii clones.
ELISA analysis of lysates and spent media
After standardization, lysates and spent media from cul-
tures of the R. rhodnii transformant were analyzed via































































Figure 5 T. cruzi Sylvio is inhibited by recombinant β-
glucanase. Indicated amounts of dialyzed lysates or spent media,
containing recombinant β-glucanase, harvested from transformed R.
rhodnii were added to cultures of T. cruzi Sylvio. Turbidity of para-
sites treated with lysates from untransformed R. rhodnii (control
lysate) was compared to that of the treatment group after 96-hours.
Results are presented as the percent change in turbidity between
treated and untreated cultures following this incubation period. The
result shown here is a representative from two independent
experiments.
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The concentrations of recombinant β-glucanase were ex-
trapolated from the standard curve of the synthetic pep-
tide. ELISA detected β-glucanase at a lower threshold of
approximately 100 nM from 0.5X spent media and 80 nM
from cellular lysates (Figure 3). Interestingly, 0.5X di-










Figure 6 Microscopic analysis of T. cruzi Sylvio following treatment w
cell lysates from untransformed R. rhodnii, or dialyzed lysates containing rec
were harvested, stained with Calcein-AM and examined at 40X.concentration of recombinant peptide than undiluted
samples (Figure 3). We conducted another set of ex-
periments to explain this finding. (1) To remove the ef-
fect of the lysis buffer, samples were dialyzed twice.
Double dialysis led to loss of the recombinant protein
(Figure 3) and was not a viable method of purification;
(2) ELISA revealed that non-specific binding of the di-
lution buffer by the antibody was not a factor (data not
shown); (3) ELISA using synthetic β-glucanase peptide
added to wild-type R. rhodnii cell extracts showed that cell
extracts block the signal from synthetic β-glucanase pep-
tide (data not shown). These experiments suggest that the
higher signal observed in diluted samples of the cell lysate
is due, in part, to dilution of the cellular extract, which en-
abled detection of the recombinant peptide. Since the
spent media samples were not affected by cellular extracts,
the increase in signal in these samples after dilution was
due to the prozone or hook effect observed in many
immuno-ligand binding assays [23].
Toxicity assays
Arthrobacter lyticase exerted approximately 50 percent
growth inhibition of T. cruzi at the lowest concentration
applied (1 U/μl) and complete inhibition at 10 and 100
U/μl (Figure 4), demonstrating that lyticase is lethal to
T. cruzi at very low concentrations. Recombinant pep-
tide samples were therefore diluted to 5% and 10%
for toxicity studies. As seen in Figure 5, recombinant
β-glucanase isolated from filtered spent media
inhibited T. cruzi growth by 50% at both dilutions.
Filtered lysates containing recombinant β-glucanase
were also diluted to 5% and 10%. These samples
inhibited T. cruzi growth by ~80% without any significant
difference in the growth inhibition between the twoFluorescent 
d
b
ith recombinant β-glucanase. T. cruzi Sylvio were treated with either
ombinant β-glucanase. Following 96-hour treatment, the parasites
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transformed R. rhodnii (negative controls) showed 0% in-
hibition of T. cruzi growth (Figures 4 and 5).
Microscopy studies confirmed the results we observed
from spectrometric toxicity assays. Brightfield and fluor-
escence microscopy demonstrated a significant reduc-
tion in the number of live T. cruzi cells after they were
treated with recombinant β-glucanase. Figure 6 shows
the microscopy images of T. cruzi treated with lysates
isolated from untransformed R. rhodnii alongside T. cruzi
treated with lysates from β-glucanase-expressing R. rhodnii.
Bright field images show a marked decrease in number of
T. cruzi after treatment with recombinant β-glucanase.
Most of the cellular debris seen under the bright field after
treatment do not fluoresce nor have the structural integrity
of healthy T. cruzi suggesting that they are lysed, unviable
remnants of T. cruzi. Additionally, since only live cells take
up the fluorescent Calcein AM and we see a decrease in
fluorescent bodies after treatment, we can conclude that
the treatment is effective in lysing T. cruzi.
Discussion and conclusions
β-glucanase is a stable molecule with cruzicidal activity
and, therefore, may play a part in a paratransgenic strat-
egy for the control of Chagas disease. Given the critical
role of the glycocalyx of T. cruzi in parasite development
within the arthropod gut, we believe that disruption of
the sugar coat using this molecule will abort vectorial
transmission. Here we report the development of transformed
R. rhodnii that express recombinant β-glucanase. This was
confirmed by the results from ELISA of lysates and spent
media isolated from an engineered line of this symbiont.
Our results suggest that the cellular lysates contain a
higher concentration of recombinant β-glucanase than
surrounding media. We observed that the blocking effect
of the cellular extract combined with a marked prozone
phenomenon resulted in under-estimation of the concen-
tration of recombinant β-glucanase in cell lysates. Never-
theless, toxicity assays revealed that any effect of T. cruzi
inhibition can be attributed entirely to the recombin-
ant β-glucanase. In ongoing studies, we are developing
expression systems for R. rhodnii that permit enhanced
secretion of heterologous proteins. We expect these
constructs to improve the efficacy of β-glucanase as an
effector molecule in the gut of triatomine bugs. How-
ever, high rates of bacterial turnover in the gut of these
bugs, especially after blood meals, will liberate recom-
binant molecules as well [15,24].
Development of recombinant β-glucanase as an ef-
fector for paratransgenesis adds another molecule to our
growing arsenal. In vitro studies have already established
that AMPs used in combination have synergistic lethal
effects against T. cruzi [19]. β-glucanase could be a
powerful addition to the system when used incombination with other molecules. Drug resistance of T.
cruzi has been a major problem with treating Chagas
disease and similar resistance could evolve to molecules
that are delivered by paratransgenic mechanisms. Use of
multiple effector molecules would help reduce develop-
ment of resistance. AMPs target cellular membranes and
internal components to exert toxicity while β-glucanase
works on sugar moieties sequestered on the surface of
the parasite. Dual targeting of T. cruzi should not only
slow resistance but also permit synergistic or additive ef-
fects on T. cruzi lethality. We have also developed re-
combinant single chain antibodies that further
strengthen the tool chest [25]. These single chain anti-
bodies, which target sialic acid epitopes on T. cruzi sur-
faces, will be used in an integrated and comprehensive
field-based strategy to target vector stages of T. cruzi, as
part of paratransgenic control of Chagas disease.
Currently, we are conducting in vivo co-infection
studies in R. prolixus nymphs using engineered lines of
R. rhodnii to study the effects of our molecules on the
arthropods and verify efficacy. Aposymbiotic nymphs
are infected with transformed R. rhodnii, allowed to
develop, and challenged with T. cruzi in a blood meal.
We have set up in vivo studies that examine the effects
of AMP combinations and recombinant β-glucanase
on arthropod maturation, fecundity and competence to
carry and permit maturation of T. cruzi. Successful
colonization of R. prolixus nymphs by the transgenic
symbionts and elimination of T. cruzi carriage in all
paratransgenic insects will set the stage for simulated
field trials.
Chagas disease remains a public health concern and an
important neglected disease. Despite efforts by govern-
ments and overall improvement in living conditions, de-
tection, and treatments, tens of millions of people are
exposed to the disease-causing parasites annually. Current
methods involving insecticides as a method of vector con-
trol work only in small domestic areas and carry high
costs. The paratransgenic method using recombinant
symbiotic bacteria may serve as a valuable adjunct in the
ongoing battle to eliminate Chagas disease.
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